Online inquiry

IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8050MR)

This product GTTS-WQ8050MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) infection research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ8050MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1766MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ10859MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ11335MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ14563MR IVTScrip™ mRNA-Anti-CD19, aCD1919(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aCD1919
GTTS-WQ15909MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA XOMA 052
GTTS-WQ3246MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ13471MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ4811MR IVTScrip™ mRNA-Anti-CD4, BT-061(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BT-061
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW